Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial

Genmab's FRα-targeted ADC rinatabart sesutecan (Rina-S) met the primary PFS endpoint and key secondary OS endpoint in the Phase 3 RAINFOL-02 trial. The trial enrolled 584 patients with platinum-resistant ovarian cancer; versus investigator's choice chemotherapy, Rina-S reduced the risk of disease progression or death by 71% and the risk of death by 57% in the ITT population.